IMO-8400 Supplemental Tables
Published: 14-09-2020| Version 2 | DOI: 10.17632/f9vx46p3fc.2
Contributor:
Description
Supplemental Tables for "A phase 2 double-blinded, placebo-controlled trial of toll-like receptor 7,8,9 antagonist, IMO-8400, in dermatomyositis"